Dernière mise à jour :
26/03/2024
Cytoprotecteur   Folinate calcium  
Injectable
Stabilité des solutions Stabilité en mélange Facteur influençant la stabilité Compatibilités Voie d’administration Bibliographie Pdf
   Structure chimique  

Noms commerciaux   Noms commerciaux     

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Antrex Finlande
Axifolin Allemagne
Bendafolin Egypte, Iran
Biofolic Italie
Calcium leucovorin Turquie
Calfolex Italie
Citofolin Italie
Cromaton Luxembourg
Dalisol Colombie, Inde, Mexique
Degalin Allemagne
Durofolin Grèce
Etamolin Pérou
Eurofolic Allemagne
Fastovorin Inde
Folcasin Roumanie
Folical Colombie
Folidan Espagne
Folinate de calcium France
Furoic Italie
Innefol Mexique
Lederfolin Grande Bretagne, Irlande, Italie
Ledervorin calcium Arabie Saoudite, Australie, Belgique, Colombie, Emirats Arabes Unis , Irlande, Luxembourg, Pologne
Leucocalcin Argentine, Chili
Leucovorin Allemagne, Autriche, Belgique, Grande Bretagne, Grèce, Hongrie, Pologne, Slovénie, Suisse, Turquie
Neofolin Allemagne
Novizet Argentine
Precileucin Mexique
Prefolic Italie
Refolinon Grande Bretagne, Grèce
Rescuvolin Afrique du sud, Allemagne, Belgique, Colombie, Grèce, Luxembourg, Malaisie, Pays bas, Suède
Ribofolin Allemagne, Autriche, Iran
Rontafor Argentine
Sanficinate Grèce
Sanifolin Italie
Tecnovorin Colombie, Pérou
Veravorin Grèce
Xanacanto Mexique
Bibliographie   Injectable   Bibliographie : Folinate calcium  
Type Source
73 Revue Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
81 Revue Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
99 Revue Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150 Revue Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
155 Revue Trissel LA, Martinez JF, Xu QA.
Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium.
Am J Health-Syst Pharm 1995 ; 52: 710-715.
182 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Revue Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Revue Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
301 Revue Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
479 Revue Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
496 Revue Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
763 Revue Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326.
905 Revue Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Revue Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1287 Revue Lecompte D, Bousselet M, Gayrard D, Poitou P.
Stability study of reconstituted and diluted solutions of calcium folinate.
Pharm Ind 1991 ; 53: 90-94.
1410 Revue Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Revue Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Revue Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Revue Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1754 Revue Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1914 Laboratoire Pemetrexed (Alimta®) - Summary of Product Characteristics
Eli Lilly 2016
1925 Revue Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Revue Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Revue Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2027 Revue Walker SE, Shirley L, Puodziunas A.
Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers.
Can J Hosp Pharm 2005 ; 58: 212-222.
2130 Revue Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J.
Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique.
Bull Cancer 1999 ; 86, 11: 946-954.
2181 Revue Milano G, Renée N.
Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique.
Bull Cancer 1995 ; 82: 189-195.
2295 Laboratoire Fosaprepitant (Emend®) - Summary of Product Characteristics
Merck Sharp Dohme 2013
2340 Revue Walker S.E, Law S, Puodziunas A.
Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers
Can J Hosp Pharm 2005 ; 58, 4: 212-222.
3474 Laboratoire Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3523 Laboratoire Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018
3546 Laboratoire Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007
3619 Laboratoire Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics
Wockhardt 2016
3621 Laboratoire Phosphate dipotassique - Résumé des caractéristiques du produit
Renaudin 2008
3634 Laboratoire Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit
Accord Healthcare 2011
3694 Revue Smith J.A, Morris A, Duafala M.E, Bertino J.R, Markman M, Kleinberg M.
Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration.
Am J Hosp Pharm 1989 ; 46: 985-989.
3753 Laboratoire Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics
Cubist Pharmaceuticals 2014
3838 Laboratoire Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007
3933 Laboratoire Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit
Teva Laboratoire 2015
4154 Laboratoire Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018
4720 Laboratoire Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021.
Paratek Pharmaceuticals 2021

  Mentions Légales